- | Portage
iNK T-Cell Immuno-oncology For Solid Tumors With Dr. Ian Walters
Dr. Ian Walters’ company, Portage Biotech, is focused on addressing the 75% of cancer patients who show no, or limited, response to existing therapies such as checkpoint inhibitors. Leading that charge are the company’s invariant natural killer T cell agonists, designed to activate the innate and adaptive immune system, as well as a growing portfolio of proteins, antibodies, and small molecules. On this episode of the Business of Biotech, Dr. Walters shares what’s fueling the company’s progress, including its unique financing strategy and its approach to de-risking platform development for novel immuno-oncology therapies.
- | Clene Nanomedicine
Going for gold: Clene ups nanocatalysis capacity to support ALS lead
Clene Nanomedicine has quadrupled production capacity to support candidate CNM-Au8, a gold nanocrystal suspension it says could be a gamechanger in the neurodegenerative disease space.
- | AltruBio
Companies To Watch: AltruBio
AltruBio is a private company developing checkpoint-regulator monoclonal antibodies (mAbs) for treating immune disorders. The company uses its checkpoint regulators in a way it believes down-modulates overactivated
- | Heat Biologics
Morrisville firm looking to fight next pandemic
Even as the world battles the coronavirus pandemic, Jeff Wolf, CEO of Morrisville-based Heat Biologics, says his company is studying potential vaccines to limit potential future viral pandemics.
- | Heat Biologics
CDC, Heat Biologics Establish New Pandemic Preparedness Initiatives
North Carolina-based Heat Biologics is also taking a proactive stance against potential pandemic threats. This week, the company established its Biothreat Advisory Board. Heat Chief Executive Officer Jeff Wolf said the board was created to support its biosecurity/biodefense initiative, which was originally conceived as a result of the ongoing pandemic.
- | BeyondSpring Pharmaceuticals
Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success
BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.
- | Check-Cap
Let’s Get to Know Yoav Kimchy, Founder and Chief Technology Officer of Check-Cap
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
- | Windtree Therapeutics
Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care
Windree Therapeutics CEO and President Craig Fraser discusses the unmet needs in acute care, Windtree’s pipeline, the importance of Fast Track designations, and how his past military career primed him for success as a pharma leader.
